Karyopharm reports first quarter 2023 financial results and highlights recent company progress

– achieved first quarter 2023 total revenues of $38.7 million, including xpovio® (selinexor) net product revenue of $28.3 million, adversely impacted by increased utilization of  patient assistant programs (pap) and higher gross to net; yoy growth in total demand1 – – rapid, deep and sustained spleen and symptom responses observed in the phase 1 study of selinexor in combination with ruxolitinib in treatment-naÏve myelofibrosis; planning to initiate pivotal phase 3 study in front-line myelofibrosis in 1h 2023 – – single-agent eltanexor showed encouraging results with a median overall survival of 8.7 months in patients with higher risk relapsed/refractory myelodysplastic neoplasms (mds) in the interim analysis of the phase 2 study – –  company revises full year 2023 total revenue guidance to $145 million to $160 million, including revised xpovio net product revenue guidance of $110 million to $125 million, reflecting increased use of pap –  – non-gaap r&d and sg&a expense guidance revised to $245 million to $260 million; company re-iterates cash runway to late 2025 – – conference call scheduled for today at 8:00 a.m. et – newton, mass.
KPTI Ratings Summary
KPTI Quant Ranking